Saentra Forge

Saentra Forge, formerly Genenta Science, is a Nasdaq-listed strategic industrial consolidator that integrates advanced biotechnology with defense and national security sectors. The company's core life sciences asset is Temferon, an autologous hematopoietic stem cell-based gene therapy platform designed to deliver interferon-alpha directly into the tumor microenvironment. Currently in Phase 1/2a clinical trials for glioblastoma multiforme, Temferon aims to reprogram the tumor microenvironment to activate anti-tumor immunity while minimizing systemic toxicity. Following a strategic pivot in early 2026, the company expanded its focus to include defense and aerospace, acquiring a controlling interest in ATC, a tactical weapons manufacturer. Saentra Forge operates as a strategic platform for integrating profitable, privately-held industrial scale-ups within regulated national security frameworks.